In agreement, TAM treatment in Mif+l+;TP53Q/Q tumors showed no decreased tumor area compared to oil treatment (Supplementary Fig. S4C) and thus, Tamoxifen have not gained unspecific effects in none of the TP53-engineered CRC mouse models. The gene discussed is MIF; the disease is colorectal carcinoma.